Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1966 1
1973 1
1974 1
1977 2
1978 1
1979 2
1980 4
1981 2
1982 2
1983 3
1985 6
1986 2
1987 3
1988 3
1989 6
1990 5
1991 2
1992 4
1993 12
1994 3
1995 4
1996 3
1997 7
1998 7
1999 6
2000 8
2001 7
2002 8
2003 10
2004 10
2005 14
2006 15
2007 14
2008 20
2009 14
2010 20
2011 21
2012 21
2013 24
2014 24
2015 26
2016 28
2017 40
2018 36
2019 52
2020 58
2021 54
2022 44
2023 55
2024 56
2025 53
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

730 results

Results by year

Filters applied: . Clear all
Page 1
Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma.
Vaisman D, Pe'er J, Eiger-Moscovich M, Lotem M, Marims S, Frenkel S. Vaisman D, et al. Am J Ophthalmol. 2026 Jan 29:S0002-9394(26)00042-5. doi: 10.1016/j.ajo.2026.01.029. Online ahead of print. Am J Ophthalmol. 2026. PMID: 41619897
CONCLUSIONS: Topical interferon alpha-2a is safe and effective for treating PAM with atypia and for PAM with atypia surrounding conjunctival melanoma that arises from PAM with atypia, with high response rates and little to no toxicity. ...
CONCLUSIONS: Topical interferon alpha-2a is safe and effective for treating PAM with atypia and for PAM with atypia surrounding conjuncti …
Metastatic disease in conjunctival malignant melanoma: a retrospective analysis of 167 cases.
Sezgin M, Rahal A, Nowack V, Manthey A, Suesskind D, Guberina M, Stuschke M, Flühs D, Sauerwein WAG, Griewank K, Schadendorf D, Herault J, Bechrakis NE, Westekemper H. Sezgin M, et al. BMJ Open Ophthalmol. 2026 Jan 30;11(1):e002172. doi: 10.1136/bmjophth-2025-002172. BMJ Open Ophthalmol. 2026. PMID: 41617257 Free PMC article.
OBJECTIVE: To analyse the data of a cohort of patients with conjunctival melanoma in order to analyse risk and guarding factors and to investigate the impact on metastatic disease with and without adjuvant therapy. ...P value of <0.05 was considered statistically …
OBJECTIVE: To analyse the data of a cohort of patients with conjunctival melanoma in order to analyse risk and guarding factor …
Ocular Surface Squamous Neoplasia Masqueraders.
Mercado C, Parra-Rosas C, Karp CL. Mercado C, et al. Semin Ophthalmol. 2026 Feb;41(2):331-341. doi: 10.1080/08820538.2025.2548021. Epub 2025 Aug 26. Semin Ophthalmol. 2026. PMID: 41549989 Review.
A rare case of conjunctival melanoma in an Asian lady: A case report.
Shandi N, Alkabbani S, Nezzar H. Shandi N, et al. Int J Surg Case Rep. 2025 Nov;136:112061. doi: 10.1016/j.ijscr.2025.112061. Epub 2025 Oct 13. Int J Surg Case Rep. 2025. PMID: 41332075 Free PMC article.
INTRODUCTION: Ocular melanoma is the second most prevalent after cutaneous melanoma. There are few studies published on conjunctival melanoma, and the literature is limited especially concerning surgical techniques of excision. ...She underwent wide local excision w …
INTRODUCTION: Ocular melanoma is the second most prevalent after cutaneous melanoma. There are few studies published on conjunctival …
Imiquimod Treatment for Conjunctival Melanoma In Situ or Ocular Surface Squamous Neoplasia.
Bowen RC, Bryar PJ, Gerami P. Bowen RC, et al. JAMA Ophthalmol. 2026 Jan 1;144(1):42-51. doi: 10.1001/jamaophthalmol.2025.4669. JAMA Ophthalmol. 2026. PMID: 41296343
IMPORTANCE: There are limited effective treatment options for diffuse conjunctival melanoma in situ (MIS), diffuse conjunctival intraepithelial neoplasia, and squamous cell carcinoma. ...Patients with a histological diagnosis of either conjunctival intraepithelial n …
IMPORTANCE: There are limited effective treatment options for diffuse conjunctival melanoma in situ (MIS), diffuse conjunctiva …
Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma.
Dimitriou F, Wu X, Nagarajan P, Glitza IC, Zhao L, Ning J, Patel SP, Wargo JA, Futreal A, Woodman S, McQuade JL, Esmaeli B. Dimitriou F, et al. NPJ Precis Oncol. 2025 Nov 19;9(1):365. doi: 10.1038/s41698-025-01143-w. NPJ Precis Oncol. 2025. PMID: 41261164 Free PMC article.
Conjunctival melanoma (CJM) is a rare and aggressive malignancy. Mainly attributed to its rarity, the genomic features of CJM have not been well characterized. ...
Conjunctival melanoma (CJM) is a rare and aggressive malignancy. Mainly attributed to its rarity, the genomic features of CJM …
Conjunctival Melanoma Arising From Nevus in a Young Woman.
Walsh SR, Chou YB, Shields CL. Walsh SR, et al. J Pediatr Ophthalmol Strabismus. 2026 Jan-Feb;63(1):76. doi: 10.3928/01913913-20250724-05. Epub 2025 Aug 26. J Pediatr Ophthalmol Strabismus. 2026. PMID: 41037488 Free article. No abstract available.
Conjunctival Melanoma: Current Management.
Krema H. Krema H. Int Ophthalmol Clin. 2025 Oct 1;65(4):9-13. doi: 10.1097/IIO.0000000000000585. Epub 2025 Sep 25. Int Ophthalmol Clin. 2025. PMID: 40993893 Review.
Conjunctival melanoma is a rare, potentially lethal cancer that mainly affects fair-skinned individuals. ...UV signature mutations are frequently observed in the bulbar conjunctival melanoma. The TNM staging classifies conjunctival melanoma …
Conjunctival melanoma is a rare, potentially lethal cancer that mainly affects fair-skinned individuals. ...UV signature mutat …
730 results